AcouSort AB (SE:ACOU)
:ACOU
Want to see SE:ACOU full AI Analyst Report?
ACOU Stock Chart & Stats
kr2.64
-kr3.18(-45.56%)
At close: 4:00 PM EST
kr2.64
-kr3.18(-45.56%)
Day’s Range― - ―
52-Week Rangekr2.03 - kr5.16
Previous CloseN/A
Volume449.84K
Average Volume (3M)29.24K
Market Cap
kr88.47M
Enterprise Valuekr75.16M
Total Cash (Recent Filing)kr14.57M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding21,163,902
10 Day Avg. Volume27,764
30 Day Avg. Volume29,240
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.27
Price to Sales (P/S)7.79
P/FCF Ratio-3.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)kr10.70M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero reported debt materially reduces solvency and refinancing risk, giving the company flexibility to fund R&D, partnerships or commercialization without immediate borrowings. This conservative capital structure supports longer-term execution despite operating volatility.
Top-line MomentumImproving TTM revenue growth signals growing commercial traction and product adoption in target markets. Sustained top-line momentum can enable scale benefits and learning-curve improvements that help move toward stable gross margins if cost or pricing levers are executed.
Differentiated Technology & MarketAcouSort's acoustofluidic modules target integration into instruments for cell therapy, diagnostics and research — a specialized niche with high technical barriers. Proprietary, instrument-integrated tech and exposure to structural growth areas support durable competitive positioning and long-term demand.
Bears Say
Unprofitable OperationsNegative gross profit and persistent operating losses indicate the core unit economics are currently unfavorable. Without structural improvements to product costs, yields, or pricing, revenue growth alone will not translate to profitability and long‑term self‑sustainability.
Weak Cash GenerationConsistent negative operating and free cash flow with a steep FCF deterioration shows ongoing cash burn and uneven cash discipline. This creates reliance on external funding, which can dilute shareholders and constrain the company's ability to invest or pivot strategically.
Eroding Equity & Low ReturnsDeclining equity and very negative ROE reflect persistent value destruction from operations. Erosion of the equity base reduces financial buffers, weakens negotiating leverage with partners or suppliers, and signals difficulties converting invested capital into sustainable returns.
ACOU FAQ
What was AcouSort AB’s price range in the past 12 months?
AcouSort AB lowest stock price was kr2.03 and its highest was kr5.16 in the past 12 months.
What is AcouSort AB’s market cap?
AcouSort AB’s market cap is kr88.47M.
When is AcouSort AB’s upcoming earnings report date?
AcouSort AB’s upcoming earnings report date is Aug 26, 2026 which is in 67 days.
How were AcouSort AB’s earnings last quarter?
AcouSort AB released its earnings results on May 27, 2026. The company reported -kr0.112 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.112.
Is AcouSort AB overvalued?
According to Wall Street analysts AcouSort AB’s price is currently Overvalued.
Does AcouSort AB pay dividends?
AcouSort AB does not currently pay dividends.
What is AcouSort AB’s EPS estimate?
AcouSort AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AcouSort AB have?
AcouSort AB has 21,163,902 shares outstanding.
What happened to AcouSort AB’s price movement after its last earnings report?
AcouSort AB reported an EPS of -kr0.112 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.139%.
Which hedge fund is a major shareholder of AcouSort AB?
Currently, no hedge funds are holding shares in SE:ACOU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AcouSort AB
AcouSort AB (publ) is a technology firm that innovates and provides automated systems for preparing biological samples. Their core methodology relies on acoustofluidics technology, catering to the needs of the research community and various life science organizations. The company's product portfolio includes several key offerings: AcouTrap: A compact laboratory instrument engineered for preparing samples containing cells, extracellular vesicles, bacteria, and viruses from diverse biological media. AcouPlasma: An integrated module capable of separating blood plasma directly from whole blood, enabling seamless in-line analytical processes. AcouWash: Another benchtop device designed for the label-free isolation of specific target cells from a wide array of samples. Established in 2010, AcouSort is headquartered in Lund, Sweden.
Technical Analysis
PILA PHARMA AB
―
OncoZenge AB
―
ExpreS2ion Biotech Holding AB
―
CombiGene AB
―
Sprint Bioscience AB
―